Faculty

Dr. James A. Russell

Dr. Russell pursued his undergraduate degree (AB) in Biology and Biochemistry at Princeton University and medical degree (MD) at the University of Toronto. He completed a residency in Internal Medicine at Toronto General Hospital and University of Toronto. He chose to go to the University of California, San Francisco for his Fellowship in Critical Care Medicine and research training. He then returned to Toronto General Hospital as Director of the Medical ICU before being recruited to Vancouver, BC as Director of the Medical Surgical ICU at St. Paul’s Hospital. He built a world-class team of basic science, translational, and clinical researchers in Critical Care focused on molecular mechanisms and treatment of sepsis. He was Chair of Medicine at St. Paul’s and Head of the Division of Critical Care Medicine for University of British Columbia (UBC).

He is now a Professor of Medicine at UBC, a Principal Investigator at the SPH-based Centre for Heart Lung Innovation (HLI) and a member of the Board of Molecular You and of the Personalized Medicine Initiative. Dr. Russell was also a co-founder and founding CEO of Sirius Genomics Inc., a spin off company of UBC and SPH. Sirius raised $16M to attempt to identify and validate genomic markers (i.e. predictive biomarkers) of improved response to what was the only approved drug for sepsis, activated protein C (Xigris). Dr. Russell is also co-founder and Chief Medical Officer of Cyon Therapeutics, another spin-off of UBC and SPH. Through their groundbreaking scientific discoveries the team is developing the means to boost the body’s natural ability to clear infectious toxins from the bloodstream. Bacterial toxins are found in cholesterol, so Cyon’s technology will focus on increasing the clearance of cholesterol bound toxins. The major discovery is that genetic variants of PCSK9 – loss of function variants – have improved survival from septic shock and that in murine models, PCSK9 knock-outs and antibodies to PCSK9 also have improved survival from septic shock. This important discovery has potentially important therapeutic implications in septic shock; we are now investigating the potential efficacy and safety of PCSK9 inhibitor(s) in septic shock.

Education:

Princeton University, A.B. Biology (Cum Laude)

University of Toronto, MD

University of Toronto, Internal Medicine Residency

University of California, San Francisco, Critical Care Medicine and Research Fellowship

Affiliations

Member, Editorial Board, Journal of Innate Immunity, 2008 – present

Member, Editorial Board, American Journal of Respiratory and Critical Care Medicine, 2012 – present

Member, Editorial Board, Annals of Intensive Care, 2012 – present

Member, Editorial Board, Intensive Care Medicine, 2015 – present

01. Refereed Publications
(a) Journals

1. Lisk RD, Russell JA, Kahler SG, Hanks JB. Regulation of hormonally mediated maternal nest structure in the mouse (Mus musculus) as a function of neonatal hormone manipulation. Anim Behav 21: 296-301, 1973.
2. Russell J, Follansbee S, Matthay M. Adult respiratory distress syndrome complicating diabetic ketoacidosis. West J Med 135: 148-150, 1981.
3. Russell JA, Hoeffel J, Murray JF. Effect of different levels of positive end-expiratory pressure on lung water content. J Appl Physiol 53: 9-15, 1982.
4. Russell JA, Joel M, Hudson RJ, Mangano DT, Schlobohm RM. Prospective evaluation of radial and femoral artery catheterization sites in critically ill adults. Crit Care Med 11: 936-939, 1983.
5. Thommasen HV, Russell JA, Boyko WJ, Hogg JC. Transient leucopenia associated with adult respiratory distress syndrome. Lancet 1: 809-812, 1984.
6. Huchon GJ, Russell JA, Barritault LG, Lipavsky A, Murray JF. Chronic air-flow limitation does not increase respiratory epithelial permeability assessed by aerosolized solute, but smoking does. Am Rev Respir Dis 130: 457-460, 1984.
7. Hjalmarson A, Herlitz J, Holmberg S, et al. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 6: 199-226, 1985.
8. Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group. AmJ Cardiol 56: 10G-46G, 1985.
9. Ostro MJ, Russell JA, Soldin SJ, Mahon WA, Jeejeebhoy KN. Control of gastric pH with cimetidine: boluses versus primed infusions. Gastro 89: 532-537, 1985.
10. Thommasen HV, Boyko WJ, Montaner JS, Russell JA, Johnson DR, Hogg JC. Absolute lymphocytosis associated with nonsurgical trauma. Am J Clin Pathol 86: 480-483, 1986.
11. Dodek PM, Thommasen HV, Russell JA, Boyko WJ, Hogg JC. Neutrophil margination in the lung in adult respiratory distress syndrome. J Crit Care. 3(3):172-179, 1988.
12. Montaner JS, Russell JA, Lawson L, Ruedy J. Acute respiratory failure secondary to Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A potential role for systemic corticosteroids. Chest 95: 881-884, 1989.
13. Mitchell P, Dodek P, Lawson L, Kiess M, Russell J. Torsades de pointes during intravenous pentamidine isethionate therapy. CMAJ 140: 173-174, 1989.
14. Fenwick JC, Dodek PM, Ronco JJ, Phang PT, Wiggs B, Russell JA. Increased concentrations of plasma lactate predict pathologic dependence of oxygen consumption on oxygen delivery in patients with adult respiratory distress syndrome. J Crit Care. 5(2)(81-86), 1990.
15. Russell JA, Wiggs BR. Oxygen kinetics: Pitfalls in clinical research revisited. J Crit Care. 5(4):213-217, 1990.
16. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 112: 492-498, 1990.
17. Ronco JJ, Montaner JS, Fenwick JC, Ruedy J, Russell JA. Pathologic dependence of oxygen consumption on oxygen delivery in acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest 98: 1463-1466, 1990.
18. Russell JA. Effect of opposite changes in cardiac output and arterial PO2 on the relationship between mixed venous PO2 and oxygen transport. Am Rev Respir Dis 141: 800-801, 1990.
19. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 34: 269-272, 1990.
20. Russell JA, Ronco JJ, Dodek PM. Physiologic effects and side effects of prostaglandin E1 in the adult respiratory distress syndrome. Chest 97: 684-692, 1990.
21. Russell JA, Ronco JJ, Lockhat D, Belzberg A, Kiess M, Dodek PM. Oxygen delivery and consumption and ventricular preload are greater in survivors than in nonsurvivors of the adult respiratory distress syndrome. Am Rev Respir Dis 141: 659-665, 1990.
22. Cooper DJ, Walley KR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study – Letter Response. Ann Intern Med 113: 254-256, 1990.
23. Ronco JJ, Phang PT, Walley KR, Wiggs B, Fenwick JC, Russell JA. Oxygen consumption is independent of changes in oxygen delivery in severe adult respiratory distress syndrome. Am Rev Respir Dis 143: 1267-1273, 1991.
24. Cooper DJ, Walley KR, Dodek PM, Rosenberg F, Russell JA. Plasma ionized calcium and blood lactate concentrations are inversely associated in human lactic acidosis. Inten Care Med 18: 286-289, 1992.
25. Walley KR, Cooper DJ, Baile EM, Russell JA. Bicarbonate does not improve left ventricular contractility during resuscitation from hypovolemic shock in pigs. J Crit Care 7: 14-21, 1992.
26. Montaner JS, Hawley PH, Ronco JJ, Russell JA, Quieffin J, Lawson LM, Schechter MT. Multisystem organ failure predicts mortality of ICU patients with acute respiratory failure secondary to AIDS-related PCP. Chest 102: 1823-1828, 1992.
27. Phang PT, Russell JA. When does V(O2) depend on D(O2)? Resp Care. 38(6), 618-630, 1993.
28. Cooper DJ, Herbertson MJ, Werner HA, Walley KR. Bicarbonate does not increase left ventricular contractility during L-lactic acidemia in pigs. Am Rev Respir Dis 148: 317-322, 1993.
29. Ronco JJ, Fenwick JC, Wiggs BR, Phang PT, Russell JA, Tweeddale MG. Oxygen consumption is independent of increases in oxygen delivery by dobutamine in septic patients who have normal or increased plasma lactate. Am Rev Respir Dis 147: 25-31, 1993.
30. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 104: 230-235, 1993.
31. Skarsgard ED, Phang PT, Belzberg AS, Russell JA. Effect of cardiac stabbing on ventricular function: evaluation by radionuclide angiography. Can J Surg 36: 425-430, 1993.
32. Ronco JJ, Fenwick JC, Tweeddale MG, Wiggs BR, Phang PT, Cooper DJ, Cunningham KF, Russell JA, Walley KR. Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA 270: 1724-1730, 1993.
33. Phang PT, Cunningham KF, Ronco JJ, Wiggs BR, Russell JA. Mathematical coupling explains dependence of oxygen consumption on oxygen delivery in ARDS. Am J Respir Crit Care Med 150: 318-323, 1994.
34. Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med 149: 533-537, 1994.
35. Fisher CJ, Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843, 1994.
36. Ronco JJ, Belzberg A, Phang PT, Walley KR, Dodek PM, Russell JA. No differences in hemodynamics, ventricular function, and oxygen delivery in septic and nonseptic patients with the adult respiratory distress syndrome. Crit Care Med 22: 777-782, 1994.
37. Hawley PH, Ronco JJ, Guillemi SA, Quieffin J, Russell JA, Lawson LM, Schechter MT, Montaner JS. Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest 106: 1456-1459, 1994.
38. Herbertson MJ, Werner HA, Goddard CM, Russell JA, Wheeler A, Coxon R, Walley KR. Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs. Am J Respir Crit Care Med 152: 480-488, 1995.
39. Herbertson MJ, Werner HA, Russell JA, Iversen K, Walley KR. Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. J Appl Physiol 79: 479-486, 1995.
40. Grant GA, Russell JA. Applied molecular biology: the molecular mechanisms of sepsis. J Crit Care 10: 78-81, 1995.
41. Hebert PC, Wells G, Marshall J, Martin C, Tweeddale M, Pagliarello G, Blajchman M. Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group. JAMA 273: 1439-1444, 1995.
42. Lemaire F, Apolone G, Blanch L, Fagon JY, Foex P, Hedenstierna G, Morel D, Parsons P, Pesenti A, Ramsay G, Simbruner G, Slutsky AS, Vincent JL, Russell J, Artigas A, Bihari D, Burchardi H, Gajdos P, Richard C, et al. Tissue hypoxia. How to detect, how to correct, how to prevent? Intensive Care Med 22(11):1250-1257, 1996.
43. Hawley PH, Chan N, Russell JA, Montaner JS. Consider anti-CMV therapy. Chest 109: 1130-1131, 1996.
44. Herbertson MJ, Werner HA, Studer W, Russell JA, Walley KR. Decreased left ventricular contractility during porcine endotoxemia is not prevented by ibuprofen. Crit Care Med 24: 815-819, 1996.
45. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 131: 1193-1201, 1996.
46. Axler O, Tousignant C, Thompson CR, Dall’ava-Santucci J, Phang PT, Russell JA, Walley KR. Comparison of transesophageal echocardiographic, Fick, and thermodilution cardiac output in critically ill patients. J Crit Care 11: 109-116, 1996.
47. Forrest DM, Russell JA, Montaner J. Focus on Pneumocystis carinii pneumonia AIDS in the intensive care unit. A Trial of antioxidants N-acetylcysteine and Procysteine in ARDS*. Chest 368-375, 1997.
48. Russell JA. Gastric tonometry: does it work? Intensive Care Med 23: 3-6, 1997.
49. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 112: 164-172, 1997.
50. Axler O, Tousignant C, Thompson CR, Dalla’va-Santucci J, Drummond A, Phang PT, Russell JA, Walley KR. Small hemodynamic effect of typical rapid volume infusions in critically ill patients. Crit Care Med 25: 965-970, 1997.
51. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336: 912-918, 1997.
52. Hebert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B, Blajchman M, Schweitzer I, Pagliarello G. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 155: 1618-1623, 1997.
53. Cook DJ, Hebert PC, Heyland DK, Guyatt GH, Brun-Buisson C, Marshall JC, Russell J, Vincent JL, Sprung CL, Rutledge F. How to use an article on therapy or prevention: pneumonia prevention using subglottic secretion drainage. Crit Care Med 25: 1502-1513, 1997.
54. McNab A, Russell JA, Lowe, Gagnon FA. Critical incident stress intervention after loss of an air ambulance: Two-year followup. Prehosp Disaster Med 27: 8-12, 1998.
55. Forrest DM, Djurdjev O, Zala C, Singer J, Lawson L, Russell JA, Montaner JS. Validation of the modified multisystem organ failure score as a predictor of mortality in patients with AIDS-related Pneumocystis carinii pneumonia and respiratory failure. Chest 114: 199-206, 1998.
56. Russell JA. Adding fuel to the fire – the supranormal oxygen delivery trials controversy. Crit Care Med 26: 981-983, 1998.
57. Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M, Pagliarello G, Schweitzer I, Calder L. A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med 26: 482-487, 1998.
58. Granton JT, Walley KR, Phang PT, Russell JA, Lichtenstein S. Assessment of three methods to reduce the influence of mathematical coupling on oxygen consumption and delivery relationships. Chest 113: 1347-1355, 1998.
59. Poon BY, Goddard CM, Leaf CD, Russell JA, Walley KR. L-2-Oxothiazolidine-4-carboxylic acid prevents endotoxin-induced cardiac dysfunction. Am J Respir Crit Care Med 158: 1109-1113, 1998.
60. Arons MM, Wheeler AP, Bernard GR, Christman BW, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson W, Wright P, Dupont WD, Swindell BB. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 27: 699-707, 1999.
61. Forrest DM, Zala C, Djurdjev O, Singer J, Craib KJ, Lawson L, Russell JA, Montaner JS. Determinants of short- and long-term outcome in patients with respiratory failure caused by AIDS-related Pneumocystis carinii pneumonia. Arch Intern Med 159: 741-747, 1999.
62. Russell JA, Brun-Buisson C, Carlet J, et al. International consensus conferences in intensive care medicine: Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societe de Reanimation de Langue Francaise, and was approved by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 160: 2118-2124, 1999.
63. Russell JA, Brun-Buisson C, Carlet J, Slutsky A, Lemaire F, Ramsay G, Mancebo J, Richard C, Marini J, Cook D, Dobb G, Hall J, Hubmayr R, Rodriguez-Roisin R, Takala J, Tobin M. International consensus conferences in intensive care medicine. Ventilator-associated lung injury in ARDS. American Thoracic Society, European Society of Intensive Care Medicine, Societe de Reanimation Langue Francaise. Intensive Care Med 25: 1444-1452, 1999.
64. Russell JA. Catecholamines and the splanchnic circulation. Crit Care Med 27: 242-243, 1999.
65. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340: 409-417, 1999.
66. Vincent JL, Slotman G, Van Leeuwen PA, Shelly M, Nasraway S, Tenaillon A, Bander J, Friedman G. IL-1ra administration does not improve cardiac function in patients with severe sepsis. J Crit Care 14: 69-72, 1999.
67. Holmes CL, Russell JA. Plasmafiltration in sepsis: removing the evil humors. Crit Care Med 27: 2287-2289, 1999.
68. Herbertson MJ, Russell JA, Walley KR. Myocardial oxygen consumption during dobutamine infusion in endotoxemic pigs. J Crit Care 14: 125-132, 1999.
69. Russell JA, Lichtenstein SL. Randomized controlled trial to determine the safety and efficacy of a multi-cell pulsating dynamic mattress system in the prevention of pressure ulcers in patients undergoing cardiovascular surgery. Ostomy Wound Manage 46: 46-51, 54-45, 2000.
70. Forrest DM, Baigorri F, Chittock DR, Spinelli JJ, Russell JA. Volume expansion using pentastarch does not change gastric-arterial CO2 gradient or gastric intramucosal pH in patients who have sepsis syndrome. Crit Care Med 28: 2254-2258, 2000.
71. Uusaro A, Chittock DR, Russell JA, Walley KR. Stress test and gastric-arterial PCO2 measurement improve prediction of successful extubation. Crit Care Med 28: 2313-2319, 2000.
72. Uusaro A, Russell JA, Walley KR, Takala J. Gastric-arterial PCO2 gradient does not reflect systemic and splanchnic hemodynamics or oxygen transport after cardiac surgery. Shock 14: 13-17, 2000.
73. Uusaro A, Russell JA. Could anti-inflammatory actions of catecholamines explain the possible beneficial effects of supranormal oxygen delivery in critically ill surgical patients? Intensive Care Med 26: 299-304, 2000.
74. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 28: 3405-3411, 2000.
75. Mangialardi RJ, Martin GS, Bernard GR, Wheeler AP, Christman BW, Dupont WD, Higgins SB, Swindell BB. Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 28: 3137-3145, 2000.
76. Holmes CL, Russell JA, Walley KR. Sepsis: Is there room for vasopressin? Sepsis. 4(2):169-175, 2001.
77. Fernandes N, Brown G, Russell J. Adrenal insufficiency in critically ill. Intensive Care Med 27: 1434, 2001.
78. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27: 1416-1421, 2001.
79. Hebert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Compendium: Management of anemia in the critically ill. Crit Care Med Supplement 29(9):S181-S188. 2001
80. Hebert PC, Blajchman MA, Cook DJ, Yetisir E, Wells G, Marshall J, Schweitzer I. Do blood transfusions improve outcomes related to mechanical ventilation? Chest 119: 1850-1857, 2001.
81. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709. 2001
82. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Jr., Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051-2059, 2001.
83. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 120: 989-1002, 2001.
84. Garber G, Gibney RTN, Light B, Martin C, Cunningham K, Guimond JG, Magder S, Russell J. Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis. Can J Infect Dis. 13(6):361-372, 2002.
85. Walley KR, Russell JA. Genetic predictors of adverse outcome from sepsis, ARDS and SIRS. Crit Care Rounds 3: 1-5, 2002.
86. von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, Walley KR, Russell JA. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 30: 1883-1892, 2002.
87. Zavorsky GS, Walley KR, Hunte GS, McKenzie DC, Sexsmith GP, Russell JA. Acute hypervolemia lengthens red cell pulmonary transit time during exercise in endurance athletes. Respir Physiol Neurobiol 131: 255-268, 2002.
88. Zavorsky GS, Van Eeden SF, Walley KR, Russell JA. Circulating white blood cells affect red cell pulmonary transit times in endurance athletes during intense exercise. Med Sci Sports Exerc 34: 954-959, 2002.
89. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96: 576-582, 2002.
90. Slutsky AS, Russell J. Genetics of critical illness: methodological issues. Crit Care Med 30: 2382-2383, 2002.
91. Russell JA. Genetics of coagulation factors in acute lung injury. Crit Care Med 31: S243-247, 2003.
92. Walley KR, McDonald TE, Wang Y, Dai S, Russell JA. Albumin resuscitation increases cardiomyocyte contractility and decreases nitric oxide synthase II expression in rat endotoxemia. Crit Care Med 31: 187-194, 2003.
93. Zavorsky GS, Walley KR, Hunte GS, McKenzie DC, Sexsmith GP, Russell JA. Acute hypervolaemia improves arterial oxygen pressure in athletes with exercise-induced hypoxaemia. Exp Physiol 88: 555-564, 2003.
94. Zavorsky GS, Walley KR, Russell JA. Red cell pulmonary transit times through the healthy human lung. Exp Physiol 88: 191-200, 2003.
95. Dhainaut JF, Russell JA, Brower R. Acute lung injury. Crit Care Med 31:183. 2003
96. Manocha S, Walley KR, Russell JA. Severe acute respiratory distress syndrome (SARS): a critical care perspective. Crit Care Med 31: 2684-2692, 2003.
97. Russell JA. Vasopressin in septic shock: clinical equipoise mandates a time for restraint. Crit Care Med 31: 2707-2709, 2003.
98. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, 3rd, Kinasewitz GT. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90: 642-653, 2003.
99. Dhainaut JF, Brower R, Russell JA. The Margaux Conference on Critical Illness: Acute Lung Injury: Understanding the Mechanisms of Injury and Repair. Crit Care Med. 31(4): 183-342. 2003
100. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124: 1103-1115, 2003.
101. Chittock DR, Dhingra VK, Ronco JJ, Russell JA, Forrest DM, Tweeddale M, Fenwick JC. Severity of illness and risk of death associated with pulmonary artery catheter use. Crit Care Med 32: 911-915, 2004.
102. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 8: R82-90, 2004.
103. Groshaus HE, Manocha S, Walley KR, Russell JA. Mechanisms of beta-receptor stimulation-induced improvement of acute lung injury and pulmonary edema. Crit Care 8: 234-242, 2004.
104. Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 18: 429-437, 2004.
105. Fuchisawa A, van Eeden S, Magee LA, Whalen B, Leung PC, Russell JA, Walley KR, von Dadelszen P. Neutrophil apoptosis in preeclampsia, do steroids confound the relationship? J Obstet Gynaecol Res 30: 342-348, 2004.
106. von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, Norena M, Walley KR, Gruslin A, Moutquin JM, Lee SK, Russell JA. The prediction of adverse maternal outcomes in preeclampsia. J Obstet Gynaecol Can 26: 871-879, 2004.
107. Shaw D, Russell JA, Walley KR. Pharmacogenomics in sepsis and septic shock. Drug Dev Res 64: 181-194, 2005.
108. Sutherland AM, Walley KR, Manocha S, Russell JA. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 165: 75-82, 2005.
109. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, Lichtenstein SV. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 130: 93-98, 2005.
110. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 33: 638-644, 2005.
111. Sutherland AM, Russell JA. Issues with polymorphism analysis in sepsis. Clin Infect Dis 41 Suppl 7: S396-402, 2005.
112. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 33: 2194-2201, 2005.
113. Wattanathum A, Manocha S, Groshaus H, Russell JA, Walley KR. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 128: 1690-1698, 2005.
114. Gordon A, Russell JA. Goal-directed therapy: how long can we wait? Crit Care 9: 647-648, 2005.
115. Sutherland AM, Gordon AC, Russell JA. Are vasopressin levels increased or decreased in septic shock? Crit Care Med 34: 542-543, 2006.
116. Manocha S, Gordon AC, Salehifar E, Groshaus H, Walley KR, Russell JA. Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care 10: R12, 2006.
117. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med. 34(9):2271-2281. 2006.
118. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care. 10:R92. 2006.
119. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF, Jr., Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 354:2564-2575. 2006. (J. Russell was Site PI of UBC site of ARDSnet).
120. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF, Jr., Hite RD, Harabin AL. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 354:2213-2224. 2006. (J. Russell was Site PI of UBC site of ARDSnet).
121. Russell JA. Management of sepsis. N Engl J Med. 355:1699-713. 2006.
122. Manocha S, Russell JA, Sutherland AM, Wattanathum A, Walley KR. Fibrinogen-beta gene haplotype is associated with mortality in sepsis. J Infect. 54:572-7. 2007.
123. Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med. 35:12-7. 2007.
124. Tokunaga C, Bateman RM, Boyd J, Wang Y, Russell JA, Walley KR. Albumin resuscitation improves ventricular contractility and myocardial tissue oxygenation in rat endotoxemia. Crit Care Med. 35:1341-7. 2007.
125. Russell JA. Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care. 13:383-91. 2007.
126. Russell JA. Vasopressin in septic shock. Crit Care Med. 35:S609-15. 2007.
127. Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, Kyle P, Lee SK, Moore MP, Moutquin JM, Smith GN, Walker JJ, Walley KR, Russell JA, von Dadelszen P. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Preg. 26:447-62. 2007.
128. Morris P, Vincent JL, Russell JA, Wheeler A, Bernard GR. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylix acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med 36 (3): 782 – 788, 2008.
129. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D for the VASST investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358: 877 – 887, 2008.
130. Meade MO, Cook DJ, Guyatt, GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell JA, Skrobnik Y, Ronco JJ, Stewart TE, and LOVS investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299(6): 637 – 645, 2008.
131. Russell JA, Wellman H, Walley KR. Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. Hum Genet 123: 661 – 663, 2008.
132. Russell JA, Walley KR. Vasopressin in septic shock. N Engl J Med 358: 2736 -2738, 2008.
133. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kalikawa O, Ruzinski JT, Rona G, Black RA, Stratton S, Jarvik GP, Hajjar AM, Nickerson DA, Rieder M, Sevransky J, Maloney JP, Moss M, Martin G, Shanholz C, Garcia J, Gao L, Brower R, Barnes KC, Walley KR, Russell JA, Marin TR. TLR-1 polymorphisms confer higher innate immune responses and susceptibility to death in sepsis. Am J Resp Crit Care Med 178: 710 – 720, 2008.
134. Russell JA. The current management of septic shock. Minerva Med 99(5): 431 – 458, 2008.
135. Russell JA. Vasopressin and its copilot copeptin in sepsis and septic shock. Crit Care Med 37(2): 749 – 750, 2009.
136. Shaw DM, Sutherland AM, Russell JA, Lichtenstein SV, Walley KR. Novel polymorphism of interleukin-18 associated with greater inflammation after cardiac surgery. Crit Care 29;13(1):R9, 2009.
137. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D for the VASST investigators. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Crit Care Med 37(3):811-818, 2009.
138. Hodder RV, Hall R, Russell JA, Fisher HN, Lee B. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort. Crit Care. 13(3):R78, 2009.
139. Nakada T, Boyd JH, Aguirre-Hernandez R, Thain K, Thair S, Nakada E, McConechy M, Russell JA, WalleyKR. Beta2-receptor gene polymorphism is associated with mortality in septic shock. Am J Resp Crit Care Med 181:143-149, 2010.
140. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Stors MM, Holmes CL Hebert JC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ for the Vasopressin and Septic Shock Trail (VASST) Investigators. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36(1):83, 2010.
141. Russell JA. Prone positioning in patients with acute respiratory distress syndrome. JAMA. 303(9):832, 2010 (Letter).
142. Russell JA, Gordon AC, Walley KR. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Corticosterstoids and the original vasopressin and septic shock trial subgroups. Crit Care Med 38(1) 338-339, 2010 (Reply).
143. Russell JA. Are copy number variants of defensins a key source of variation in the orchestrated response to infection? Anesthesiol 112(6):1307-1308, 2010.
144. Russell JA, Walley KR. Vasopressin and its immune effects in septic shock. J Innate Immun 2:446-360, 2010.
145. Russell JA. Vasopressin, levosimendan and cardiovascular function in septic shock. Crit Care Med 38(10): 2071-2073, 2010.
146. Russell JA. Gene expression in human sepsis. What have we learned? Crit Care 15(1):121, 2011.
147. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton-Pipkin F, Cote AM, Douglas JM, Gruslin A, Hutcheon JA, Joseph KS, Kyle PM, Lee T, Loughna P, Menzies JM, Merialdi M, Millman AL, Moore MP, Moutquin JM, Ouellet AB, Smith GN, Walker JJ, Walley KR, Walters BN, Widmer M, Lee SK, Russell JA, Magee LA for the PIERS Study Group. Predicting adverse maternal outcomes in pre-eclampsia: the fullPIERS (Pre-eclampsia Integrated Estimate of RiSk) model – development and validation. Lancet 377(9761):219-227, 2011.
148. Boyd JH, Forbes J, Nakada T, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 38(2):259-265, 2011.
149. Thair SA, Walley KR, Nakada T, McConechy MK, Boyd JH, Russell JA. A single nucleotide polymorphism in NF-B inducing kinase is associated with mortality in septic shock. J Immunol 186:2321-2328, 2011.
150. Boyd JH, Walley KR, Russell J. Fluid balance and central venous pressure in sepsis: Small pieces in an enormous puzzle. Crit Care Med. 39(5):1239, 2011.
151. Sutherland AM, Sham AHP, Wurfel MM, Walley KR, Russell JA. A Non-synonymous polymorphism of IRAK4 associated with increased prevalence of Gram-positive infection and decreased response to Toll-like receptor ligands. J Innate Immune 3:447-458, 2011.
152. Russell JA. Vasopressin in the management of septic shock. Critical Care 14:R140, 2011.
153. Russell JA, Boyd J, Nakada T, Thair SA, Walley KR. Molecular mechanisms of sepsis. Contrib Microbiol 17:48-85, 2011.
154. Nakada T, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR, Thair SA, Hirasawa H, Oda S, Walley KR. Leucyl/cystinyl aminopeptidase (LNPEP) gene variants in septic shock. Chest 139(5): 1042-1049, 2011.
155. Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care 15:226, 2011.
156. Nakada TA, Russell JA, Boyd JH, McLaughlin L, Nakada E, Thair SA, Hirasawa H, Oda S, Walley KR. Association of angiotensin II Type 1 receptor-associated protein (AGTRAP) gene polymorphism with increased mortality in septic shock. Crit Care Med 39(7):1641-1648, 2011.
157. Mehta S, Granton J, Lapinsky SE, Newton G, Bandayrel K, Little A, Siau S, Cook DJ, Ayers D, Singer J, Lee TCK, Walley K, Storms M, Cooper J, Holmes CL, Hebert P, Gordon A, Presneill J, Russell JA. Agreement in ECG interpretation in patients with septic shock. Crit Care Med 39(9):2080-2086, 2011.
158. Nakada T, Russell JA, Boyd JH, Walley KR. IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis. Crit Care 15:R254, 2011.
159. Bracht H, Calzia E, Georgieff M, Singer J, Radermacher P, Russell JA. Inotropes and vasopressors: more than hemodynamics. Br J Pharmacol 165(7):2009-2011, 2012. online DOI: 10.1111/j.1476-5381.2011.01776.x, 2011.
160. Russell JA, Sweet D, Boyd J, Walley KR. Septic shock: Management and challenges in developing new drug treatments. Open Access Emerg Med (In press).
161. Russell JA. “She’s out of the ICU.” “That’s a relief” The growing problem of ICU recidivism. Am J Resp Crit Care Med 185:906-908, 2012.
162. Sweet D, Marsden J, Ho K, Krause C, Russell JA. Emergency management of sepsis: the simple stuff saves lives. BC Med J 54(4):176-182, 2012.
163. Thain KR, Nakada T, Boyd JH, Russell JA, Walley KR. Common polymorphism in the 5’ region of the human protein C gene binds USF1. Thromb Res 130(3):451-457, 2012. http://dx.doi.org/10.1016/j.thromres.2012.02.045.
164. Wacharasint P, Nakada T, Boyd JH, Russell JA, Walley KR. Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock 38(1):4-10, 2012. DOI: 10.1097/SHK.0b013e318254d41a.
165. Russell JA. Control of fever in septic shock. Should we care or intervene? Am J Resp Crit Care Med 185:1040-1041, 2012. doi:10.1164/rccm.201202-0346ED
166. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared to norepinephrine in septic shock. Chest 142(3):593-605, 2012. doi:10.1378/chest.11-2604.
167. Annane D, Mira JP, Ware LB, Gordon AC, Sevransky J, Stuber F, Heagerty PJ, Wellman HF, Neia M, Mancini ADJ, Russell JA. Design, conduct and analysis of a multicenter pharmacogenomic biomarker study in matched patients with severe sepsis treated with or without drotrecogin alfa (activated). Ann Int Care 2:15, 2012.
168. Russell JA. How much fluid resuscitation is optimal in septic shock? Crit Care 16:146, 2012.
169. Wacharasint P, Nakada T, Boyd JH, Russell JA, Walley KR. AA genotype of IL-8 -251A/T is associated with low PaO2/FiO2 in critically ill patients and with increased IL-8 expression. Respirology 1440-1843, 2012. DOI: 10.1111/j..02244.x.
170. Hsu JL, Liu V, Patterson AJ, Martin G, Russell JA. Use of vasopressin and corticosteroids in septic shock. Crit Care 16:447, 2012. doi:10.1186/cc11460.
171. Neto AS, Junior AP, Cardosa SO, Manetta, JA, Pereira VGM, Esposito DC, Damasceno MT, Russell JA. Vasopressin and terlipressin in vasodilatory shock: A systematic review and meta-analysis of 11 randomized controlled trials. Crit Care 16(4):R154, 2012. doi:10.1186/cc11469
172. Thair S, Russell JA. Sepsis in transit: from clinical to molecular classification. Crit Care 16:173, 2012.
173. Russell JA. Biomarker (BNP)-guided weaning from mechanical ventilation – time for a paradigm shift? Am J Resp Crit Care Med 186: 1202-1204, 2012. doi:10.1164/rccm.201210-1770ED
174. Gordon AC, Russell JA. Vasopressin guidelines in Surviving Sepsis Campaign: 2012. Crit Care Med 41 (12), 2013. doi: 10.1097/CCM.0b013e3182916fd3.
175. Mehta S, Granton J, Gordon AC, Lapinsky S, Newton G, Bandayrel K, Little A, Siau C, Cook DJ, Ayers D, Singer J, Lee TCK, Walley KR, Storms M, Cooper DJ, Holmes CL, Hebert P, Presneill J., Russell JA. Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Crit Care 17:R117, 2013.
176. Russell JA, Walley KR. Update on sepsis in 2012. Am J Resp Crit Care Med 1303-1307, 2013.
177. Wacharasint P, Boyd JH, Russell JA, Fjell CD, Walley KR. One size does not fit all in severe infection: Obesity alters susceptibility, treatment, response, and outcome. Crit Care 17:R122, 2013.
178. Russell JA, Fjell CD, Hsu JL, Lee T, Boyd J, Thair S, Singer J, Patterson AJ, Walley KR. Vasopressin compared to norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Resp Crit Care Med 188 (3): 356-364, 2013. doi:10.1164/rccm.201302-03550C.
179. Thair S, Russell JA. Non-canonical nuclear factor kappa B (NF-B) signaling and potential for therapeutics in sepsis. Curr Inf Dis Reports 15(5):364-71, 2013. doi: 10.1007/s11908-013-0362-0.
180. Russell JA, Vincent JL. The new trials of early goal-directed resuscitation: three part harmony or disharmony? Int Care Med 39 (10):1867-1869, 2013.
181. Bernard GR, Francois B,Mira J-P, Vincent J-L, Dellinger RP, Russell JA, LaRosa SP, Laterre P-F, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Evaluating the efficacy and safety of two doses of the polyclonal anti-TNF-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled Phase IIb study. Crit Care Med 2013 doi: 10.1097/CCM.0000000000000043.
182. Fjell CD, Thair S, Hsu JL, Walley KR, Russell JA, Boyd J. Cytokines and signaling molecules predict clinical outcomes in sepsis. PLOS ONE 8(11): e79207, 2013. doi:10.1371/journal.pone.0079207
183. Wong HR, Lindsell CJ, Pettilä V, Meyer NJ, Thair SA, Karlsson S, Russell JA, Fjell CD, Boyd JH, Ruokonen E, Shashaty, Michael GS, Christie JD, Hart KW, Lahni P, Walley KR. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2013. doi: 10.1097/CCM.0000000000000106
184. Fjell CD, Russell JA. Could altered leukocyte gene expression profile in trauma patients guide immune interventions to prevent gram-negative bacteremia? Crit Care Med 42(6):1550-1551, 2014.
185. Anantasit N, Boyd JH, Russell JA, Walley KR. Prolonged QTc is associated with adverse outcomes in patients with normal left ventricular function undergoing cardiac surgery. J Thor Card Surg 147(5):1627-1633, 2014.
186. Fjell CD, Russell JA, Boyd JH. The meta-genome of sepsis: Host genetics, pathogens and the acute immune response. J Innate Imm 6:272-283, 2014 (DOI: 10.1159/000358835).
187. Russell JA, Boyd JH. Metagenomics and innate immunity – a unique partnership or battlefield? J Innate Imm 6:251-252, 2014 (DOI: 10.1159/000359977).
188. Anantasit N, Boyd JH, Walley KR, Russell JA. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock.
Crit Care Med 42(8):1812-1820, 2014. doi: 10.1097/CCM.0000000000000333.
189. Russell JA. Is there a good MAP for septic shock?
N Engl J Med 370:1649-1651, 2014. DOI: 10.1056/NEJMe1402066.
190. Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH. Small acute increases in serum creatinine are associated with decreased long term survival in the critically ill.
Am J Resp Crit Care Med 189:1075-1081, 2014. DOI: 0.1164/rccm.201311-2097OC.
191. Linder A, Guh D, Boyd J, Walley KR, Anis A, Russell JA. Long term (10 year) mortality of younger previously healthy severe sepsis patients is worse than nonseptic patients and general population. Crit Care Med 42(10):2211 – 2218, 2014. Jul 22. PMID: 25054672.
192. Vincent JL, Russell JA, Jacob M, Martin G, Guidet B, Wernerman J, Ferrer R, McCluskey SA, Gattinoni L. Albumin administration in the acutely ill: What’s new and where next?
Crit Care 18:23, 2014.
193. Linder A, Russell JA. An exciting candidate therapy for sepsis –Ulinastatin, a urinary protease inhibitor. Int Care Med 40(8):1164-1167, 2014.
194. Meyer NJ, Ferguson JF, Feng R, Wang F, Patel PN, Li M, Xue C, Qu L, Liu Y, Boyd JH, Russell JA, Christie JD, Walley KR, Reilly MP. A functional synonymous coding variant in the IL1RN gene associates with survival in septic shock.
Am J Resp Crit Care Med 190(6): 656-664, 2014.
195. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada T, Fjell CD, Thair SA, Cirstea MS, Boyd JH. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Science Trans Med 15 October 2014 6:258ra143. DOI:10.1126/scitranslmed.3008782.
196. Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, Fjell CD, Boyd JH, Hancock REW. An endotoxin tolerance signature predicts sepsis and organ failure at first clinical presentation. eBiomedicine 1(1):64-71, 2014.
197. Linder A, Russell JA. Long-term (10 year) mortality of younger previously healthy severe sepsis patients is worse than nonseptic patients and general population.
Crit Care Med 43(2):e57-e58, 2015.
198. Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri M, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider M, Reinhart K, Holloway PAH, Knight J, Garrard CS, Russell JA, Walley KR, Stüber F, Hill AVS, Hinds CJ, for the ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia. Lancet Resp Med 3(1):53 – 60, 2014.
199. Wong H, Walley K, Pettila V, Meyer N, Russell J, Karlsson S, Shashaty M, Lindsell C. Comparing the prognostic performance of ASSIST to interleukin-6 and procalcitonin in patients with severe sepsis or septic shock. Biomarkers 12:1-4, 2015.
200. Nakada T, Russell JA, Wilkinson M, Aguirre R, McConechy M, Fjell C, Nakada E, Boyd JH, Thair SA, Walley KR. Identification of a non-synonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock. Crit Care Med 43(1):101- 108, 2015. doi: 10.1097/CCM.0000000000000604.
201. Nakada T, Thair S, Russell JA, Boyd JH, Walley KR. VPS13D gene variant is associated with altered IL-6 production and mortality in septic shock. J Inn Immmunity 7:545-553, 2015.
202. Bentzer P, Russell JA, Walley KR. Advances in sepsis research.
Clin Chest Med 36(3):521–530, 2015. doi: 10.1016/j.ccm.2015.05.009.
203. Russell JA, Møller MH, Annane D. Early goal-directed therapy: from discovery through enthusiasm to equipoise? Int Care Med 41(9):1676- 1678, 2015. DOI 10.1007/s00134-015-3857-3.
204. Russell JA, Walley KR. Sepsis breakthroughs in 2014. F1000 Research 4 (F1000 Faculty Rev):131, 2015 (doi: 10.12688/f1000research.6565.1).
205. Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange-Jendeberg A, Paulsson M, Nyberg P, Russell JA, Pritchard D, Christensson B, Åkesson P. Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. Crit Care Med 43;2378 – 2386, 2015.
206. Russell JA. C-terminal portion of pro-arginine-vasopressin (CT-PRO-AVP) as a predictive biomarker in sepsis – Not there yet. Shock 44(4):381-2, 2015.
207. Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JB. The central role of PCSK9 in pathogen lipid transport and clearance.
Am J Resp Crit Care Med 192:1275 – 1286, 2015. PMID: 26252194.
208. Thair SA, Topchiy E, Boyd JH, Cirstea M, Wang C, Nakada T, Fjell C, Wurfel M, Russell JA, Walley KR. Tumor Necrosis Factor alpha induced protein 2 (TNFAIP2) inhibits early TNF [alpha] induced NF-[kappa]B signaling and decreases survival in septic shock patients.
J Inn Immunity 8:57 – 66, 2016. (Sept 15, 2015 Epub.)
209. Douglas J, Russell JA. The role of genomics to identify biomarkers and signaling molecules during severe sepsis. Minerva Anestesiologica 82 (3):343-58, 2016.
210. Harhay MO, Russell JA. Designing better, not just bigger, multicenter critical care trials.
Crit Care Med 44(1):e48 – e49, 2016.
211. Wang F, Meyer N, Walley KR, Russell JA, Feng R. Causal genetic inference using haplotypes as instrumental variables. Genetic Epidemiology 40(1):35 – 44, 2016.
212. Asfar P, Russell JA, Tuckermann J, Radermacher P. Selepressin in septic shock –a step towards “decatecholaminization”? Crit Care Med 44(1):234 – 236, 2016.
213. Boyd JH, Fjell C, Russell JA, Sirounis D, Cirstae M, Walley KR. Increased PCSK9 levels during the development of cardiovascular and respiratory failure.
J Innate Imm 8:211 – 220, 2016. DOI:10.1159/000442976.
214. Gelinas J, Russell JA. Vasopressors during sepsis: selection and targets.
Clinics in Chest Medicine 37(2):251 – 262, 2016.
215. Genga K, Russell J. Early liberal fluids in sepsis patients are harmful. Crit Care Med 44(12):2258 – 2262, 2016. (epub May 13, 2016 – doi: 10.1097/CCM.0000000000001829).
216. Russell JA, Williams M. Trials in critical care that show increased mortality of the new intervention – inevitable or preventable mishaps? Ann Int Care 6:17, 2016.
217. Fisher J, Douglas JJ, Boyd JH, Walley KR. Russell JA. Elevated plasma angiopoietin-2 levels are associated with fluid overload, organ dysfunction and mortality in human septic shock. Crit Care Med 44(11): 2018 – 2027, 2016. doi: 10.1097/CCM.0000000000001853.
218. Linder A, Fisher J, Boyd J, Walley KR, Russell JA. Short-term organ dysfunction is associated with long-term (10 year) mortality of septic shock.
Crit Care Med 44(8):e728-36, 2016. doi: 10.1097/CCM.0000000000001843.
219. Pisitsak C, Lee JGH, Boyd J, Coxon H, Russell JA, Walley KR. Increased ratio of visceral to subcutaneous adipose tissue in septic patients is associated with adverse outcome.
Crit Care Med 44(11):1966 – 1973, 2016. doi: 10.1097/CCM.0000000000001870.
220. Mebazaa A, Laterre PF, Russell JA, Bergmann A, Angus D, Gattinoni L, Gayat E, Harhay M, Hartmann O, Hein F, Kjolbye AL, Legrand M, Lewis RJ, Marshall J, Marx G, Radermacher P, Schroedter M, Scigalla P, Struck J, Van Den Berghe G, Yilmaz MB. Considerations for clinical endpoint selection in sepsis Phase 3 trials.
J Int Care 4:24, 2016. DOI: 10.1186/s40560-016-0151-6.
221. Bentzer P, Fjell CD, Walley KR, Boyd J, Walley KR, Russell JA. Plasma cytokine levels predict response to corticosteroids in septic shock. Int Care Med Exp 42(12):1970 – 1979, 2016.
222. Topchiy E, Cirstea M, Kong HJJ, Boyd JH, Wang Y, Russell JA, Walley KR. Lipopolysaccharide is cleared from the circulation by hepatocytes via the Low Density Lipoprotein Receptor. PlosOne 2016 May 12 http://dx.doi.org/10.1371/journal.pone.0155030.
223. Russell JA. Genomics and pharmacogenomics of sepsis – so close and yet so far.
Crit Care 20:185, 2016. DOI 10.1186/s13054-016-1374-6.
224. Reuter DA, Russell JA, Mekonto Dessap A. Beta-blockers in septic shock to optimize hemodynamics-pro. Int Care Med 42(10): 1607 – 1609, 2016. (Online first September 2016).
225. Russell JA. Physician culture and vasopressin use in septic shock.
Ann ATS 13(10):1677 – 1679, 2016.
226. Suetrong B, Pisitsaka C, Boyd JB, Russell JA, Walley KR. Hyperchloremia and moderate increase in serum chloride are associated with acute kidney injury in severe sepsis and septic shock patients. Critical Care 20:315, 2016. DOI: 10.1186/s13054-016-1499-7
227. Bentzer P, Fisher J, Kong J, Morgelin M, Boyd JH, Walley KR, Russell JA, Linder A. Heparin-binding protein is important for vascular leak in sepsis.
Int Care Med Exp 4:33, 2016.
228. Perner A, Gordon A, de backer D, Dimopoulos G, Lipman J, Jensen JU, Russell JA, Myburgh J, Singer M, Bellomo R, Walsh T. Sepsis – Frontiers in diagnosis, resuscitation and antibiotic therapy. Int Care Med 42(12):1958 – 1969, 2016.
229. Russell JA. Vasopressin, norepinephrine, and vasodilatory shock after cardiac surgery – another “VASST difference? Anesthesiology 126:9 – 11, 2016
230. Dunser M, Russell JA. Getting down to the real question: effects of transfusion triggers on long-term survival and quality of life following septic shock.
Int Care Med 42(11):1766 – 1769, 2016.
231. Cirstea M, Walley KR, Russell JA, Boyd JH. Low plasma HDL concentration is an early prognostic biomarker of poor outcome in sepsis. J Crit Care 38:289 – 294, 2017.
232. Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF. Angiotensin II for the Treatment of High Output Shock 3 (ATHOS-3): a study protocol for a Phase 3 double-blinded randomized controlled trial.
Crit Care Resuscitation 19(1):43-49, 2017.
233. Russell JA, Lee T, Singer J, Boyd J, Walley KR. The new septic shock 3.0 definition and trials: a VASST experience. Crit Care Med 45(6):940 – 948, 2017. doi:10.1097/CCM.0000000000002323.
234. Genga K, Lo C, Cirstea M, Zhou G, Walley KR, Russell JA, Levin A, Boyd J. 2-year follow-up of septic patients presenting with low HDL: the effect upon acute kidney injury, death and eGFR. J Int Med 2017, 281(5):518–529.
235. Rush B, McDermid RC, Celi LA, Walley KR, Russell JA, Boyd JH. Association between chronic exposure to air pollution and mortality in the acute respiratory distress syndrome.
J Env Pollution 2017, 224:352-356. doi: 10.1016/j.envpol.2017.02.014.
236. Fisher J, Boyd J, Walley KR, Russell JA, Linder A. Heparin-binding Protein (HBP): a prognostic and causative biomarker of Acute Kidney Injury and a potential target for heparin treatment in human septic shock. Shock 2017, 48(3):313-320.
doi: 10.1097/SHK.0000000000000862.
239. Genga KR, Russell JA. How much excess fluid impairs outcome of sepsis?
Int Care Med 43(5):680 – 682, 2017.
240. Rush B, Wiskar K, Celi L, Walley KR, Russell JA, McDermid R, Boyd JH. Association of household income level and in-hospital mortality in sepsis patients: a nationwide retrospective cohort analysis. J Intensive Care 2017. an 1:885066617703338.
doi: 10.1177/0885066617703338.
241. Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA, Timsit JF, Myburgh J, Shankar-Hari M, Singer M. The intensive care medicine research agenda on septic shock.
Int Car Med 2017, 43(9):1294-1305. doi: 10.1007/s00134-017-4821-1.
242. Genga KR, Russell JA. Update of sepsis in the ICU. J Inn Immunity 2017, 9:441-455.
243. Russell JA, Vincent JL, Kjolbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L. Selepressin, a novel selective vasopressin V1a agonist, is an effective substitute for norepinephrine in a Phase IIA randomized placebo- controlled trial in septic shock patients. Crit Care 21:213, 2017.
244. Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochwerg B, Rodgers, Russell JA, Van den Berghe G. Guidelines for the diagnosis and management of critical illness related corticosteroid insufficiency (CIRCI) in critically ill adult and pediatric patients (Part I. from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).
Int Care Med and Crit Care Med 2017, 45(12):2078-2088.
245. Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochwerg B, Rodgers, Russell JA, Van den Berghe G. Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).
Int Care Med and Crit Care Med 2017, 45(12):2089-2098.
246. Teboul JL, Duranteau J, Russell JA. Novel vasopressors for septic shock. Int Care Med. 2018;44(7):1130-1132. Aug 31. doi: 10.1007/s00134-017-4909-7.
247. Lewis R, Angus D, Laterre P, Kjolbye AL, Blemings A, Graves T, Russell J, Carlsen J, Jacoben K, Yealy D, Opal S, Windelov N, Francois B, Perner A, Pickkers P, Berry S. Rationale and design of an adaptive Phase 2b/3 clinical trial of selepressin for adults in septic shock: SEPSIS-ACT. Ann Am Thor Soc 2018, 15(2):250-257.
248. Nakada T, Wacharasint P, Russell JA, Boyd J, Nakada E, Thai S, Shimada T, Walley KR. IL-20 genetic polymorphism is associated with altered clinical outcome in septic shock.
J Inn Immun 2018 10(3):181 – 188. doi: 10.1159/000486104.
249. Fisher J, Linder A, Bentzer P, Boyd J, Kong HJ, Lee T, Walley KR, Russell JA. Is heparin- binding protein (HBP) inhibition a mechanism of albumin’s efficacy in human septic shock?
Crit Care Med 2018;46(5):e364-e374. doi: 10.1097/CCM.0000000000002996.
250. Annane D, Mira JP, Ware LB, Gordon AC, Christiani DC, Sevransky J, Buchman TG, Heagerty PJ, Wellman HF, Neira, M, Mancini ADJ, Walley KR, Russell JA. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.
Ann Int Care 2018, 8:16.
251. Russell JA. Vasopressin vs. norepinephrine in CVS surgery.
Anesthesiology 2018, 128(1):230-231.
252. Russell JA, Rush BR, Boyd JH. Pathophysiology of septic shock.
Crit Care Clinics 2018, 34:43–61.
253. Lee JGH, Genga KR, Pisitsak C, Boyd JH, Leung AKK, Russell JA, Walley KR. Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis. Crit Care 2018, 22:58. doi: 10.1186/s13054-018-1985-1.
254. Genga KR, Shimada T, Boyd JH, Walley KR, Russell JA. The understanding and management of organism toxicity in septic shock. J Innate Immunity May 15, 2018:1 – 13. (DOI:10.1159/000487818).
255. Russell JA, Lee T, Singer J, de Backer D, Annane D. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. J Crit Care 2018, 47:333 – 337. May 12. doi: 10.1016/j.jcrc.2018.05.003.
256. Wiskar KJ, Celi LA, McDermid RC, Walley KR, Russell JA, Boyd JH, Rush B. Patterns of palliative care referral in patients admitted with heart failure requiring mechanical ventilation. Am J Hosp Pall Care 2018, 35(4):620 – 626.
257. Russell JA, Spronk P, Walley KR. Using multi ‘omics strategies for novel therapies in sepsis. Int Care Med 2018, 44(4):509 – 511.
258. Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G, Olsen K, Osborn T Peake S, Russell JA, Zanotti S. A global perspective on vasoactive agents in shock. Int Care Med 2018,44(6):833-846. doi: 10.1007/s00134-018-5242-5.
259. Gordon AC, Russell JA. Innovation and safety in critical care: should we collaborate with the industry? Pro. Int Care Med 2018, 44(12): 2276- 2278. doi: 10.1007/s00134-018-5306-6.
260. Russell JA, Wellman H, Walley KR. Vasopressin versus norepinephrine in septic shock: A propensity scored matched efficiency retrospective cohort study in the VASST coordinating center hospital. J Int Care 2018, 6:73. doi.org/10.1186/s40560-018-0344-2
261. Trinder M, Roveran Genga K, Kong HJ, Lo C, Li X, Cirstea M, Russell JA, Walley KR, Boyd JH, Brunham LR. Cholesteryl ester transfer protein genotype influences high-density lipoprotein levels and survival during sepsis. Am J Resp Crit Care Med 2018, 199(7):854-862. doi: 10.1164/rccm.201806-1157OC.
262. Bhatraju PK, Zelnick lr, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, Robinson-Cohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, SlivinskiNSJ Russell JA, Walley KR, Christiani DC, Liles C, Himmelfarb J, Wurfel MM. Identification of Acute Kidney Injury sub-phenotypes with differing molecular signatures and response to vasopressin therapy. Am J Resp Crit Care Med 2018, 199(7):863-872.
doi: 10.1164/rccm.201807-1346OC.
263. Russell JA. When and how to use predictive biomarkers for corticosteroid treatment of shock. Crit Care 2018. 22:318. https://doi.org/10.1186/s13054-018-2254-z.
264. Vincent JL, Nielsen ND, Shapiro NI, Gerbasi ME, Grossman A, Doroff R, Zeng F, Young P, Russell JA. Mean arterial pressure and mortality in patients with distributive shock: A retrospective study based on MIMIC-III. Ann Int Care 2018,8:107.
doi: 10.1186/s13613-018-0448-9.
265. Roveran Genga K, Trinder M, Kong HJ, Leung AKK, Shimada T, Walley KR, Russell JA, Brunham L, Francis GA, Boyd JH. Cholesterylester Transfer Protein (CETP) genotype R468Q is associated with increased risk of sepsis-associated Acute Kidney Injury (AKI).
Sci Reports 2018, 8:16764. doi: 10.1038/s41598-018-35261-2.
266. Roveran Genga K, Lo C, Cirstea MS, Walley KR, Russell JA, Linder A, Francis GA, Boyd JH.
The impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. eBioMedicine 2018,38:257-264.
267. Kong J, Boyd JH, Russell JA, Walley KR. Low LDL levels are associated with, but do not causally contribute to, increased mortality in sepsis. Crit Care Med 2019, 47(3):463 – 466.
268. Walley KR, Boyd JH, Kong J, Russell JA. PCSK9 loss-of-function genotype is beneficial in septic shock while HMGCR genotype is not: Lack of LDL effect. Crit Care Med 2019 (In press).
269. Fisher J, Linder A, Caironi P, Russell JA. Hypoalbuminemia and the risk of acute kidney injury in sepsis. Crit Care Med 2019, 47(4):e378-e379.
270. Pickkers P, Russell JA. Treatment with a polymyxin B filter to capture endotoxin in sepsis patients. Is there a signal for therapeutic efficacy? Int Care Med 2019, 45(2):282-283.
271. Nakada T, Takahashi W, Nakada E, Shimada T, Russell JA, Walley KR. Genetic polymorphisms in sepsis and cardiovascular disease. Do similar risk genes suggest similar drug targets? Chest 2019, 155(6):1260-1271. (online January 17, 2019). https://doi.org/10.1016/j.chest.2019.01.003
272. Russell JA, Gordon AC, Walley KR. Early may be better – early low-dose norepinephrine in septic shock. Am J Resp Crit Care Med 2019;199(9):1049-1051.
273. Linder A, Fjell C, Inghammer M, Hsu J, Walley KR, Boyd J, Russell JA. Specific pathogens but not bacterial gram type determine the inflammatory response in human septic shock. J Innate Immunity 2019, 26:1-9.
274. Williams MD, Russell JA. Terlipressin or norepinephrine in septic shock:
do we have the final answer? J Thor Dis 2019,11(9): doi: 10.21037/jtd.2019.05.07
275. Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L, Mason AJ, Ashby D, Gordon AC. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Int Care Med 2019, 45(6):844-855. May 6. doi: 10.1007/s00134-019-05620-2.
276. Vincent JLV, Francois B, Zabolotskikh I, Kumar Daga M, Lascarrou J-B, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Margarth Lobo S, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira J-P, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D, for the SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin (ART-123) on mortality in patients with sepsis associated coagulopathy. JAMA 2019, 321(20):1993-2002. May 19. doi: 10.1001/jama.2019.5358.
277. Laterre P-F, Berry SM, Blemings A, Carlsen JE, Francois B, Graves T, Jacoben K, Lewis RJ, Opal SM, Perner A, Pickkers P, Russell JA, Windeløv NA, Yealy DM, Asfar P, Bestle MH, Boulain T, Bruel C, Brulé N, Decruyenaere J, Dive A-M, Dugernier T, Krell K, Lefrant J-Y, Megarbane B, Mercier E, Mira J-P, Quenot J-P, Rasmussen BS, Thorsen-Meyer H-C, Laenen MV, Vang ML, Vignon P, Vinatier I, Wichmann S, Wittebole X, Kjølbye AL, Angus DC on behalf of the SEPSIS-ACT Investigators. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA 2019, Oct 2. doi: 10.1001/jama.2019.14607.
278. Leung AKK, Roveran Genga K, Topchiy E, Cirstea M, Shimada T, Fjell C, Russell JA, Boyd JH, Walley KR. Reduced PCSK9 function increases LTA clearance and improves outcomes in gram positive septic shock patients. Sci Reports 2019, 9(1):10588.
279. Russell JA, Sevransky J. Toward increased understanding of the steroid controversy in septic shock. (Invited Foreward). Crit Care Med (In press 2019).
doi: 10.1097/CCM.0000000000004038
280. Genga KR, Boyd J, Russell JA. Once or twice daily screening for weaning the critically ill –
have we set our sights too low? Crit Care Med 2019, 47(6):874-875.
281. Shimada T, Topchi E, Leung A, Kong. HJ, Genga JR, Boyd JH, Russell JA, Oda S, Nakada T, Hirasawa H, Walley KR. Very Low Density Lipoprotein Receptor sequesters lipopolysaccharide into adipose tissue during sepsis. Crit Care Med (In press 2019).
282. Russell JA. Vasopressor therapy in critically ill patients with shock. Int Care Med Invited State of the Art review. (In press 2019).

02. Non-Refereed Publications

(a) Journals
1. Russell JA. The evolving role of intensive care units. BC Med J. 25:447-449. 1983
2. Russell JA. Respiratory complications in poisoning. Med North America. 12:1142-1146. 1984
3. Russell JA. Sepsis syndrome. Med North America. 3:541-550. 1986
4. Russell JA. Adult respiratory distress syndrome. Med North America. 22:4232-43. 1988
5. Russell JA. Sudden cardiac death syndrome. Med North America. 3:239-247. 1990
6. Herbertson MJ, Russell JA. Noncardiogenic pulmonary edema. The adult respiratory distress syndrome. Drug Therapy. 1993
7. Russell JA. Oxygen delivery and oxygen consumption. Crit Care Alert. 1(3):22-24. 1993
8. Russell JA. Global assessment of oxygen delivery and oxygen consumption. Proceedings of Sixth European Congress on Intensive Care Medicine. 121-123. 1992.

(b) Conference Proceedings

1. Lemaire F, Apolone G, Blanch L, et al. 3e Conference de Consensus Europeene en Reanimation. Comment mettre en evidence, corriger et prevenir l hypoxie tissulaire chez les malades de reanimation. Reanimation Urgences; 5(2): 161-320, 1996 (Conference Proceedings – Consensus Conference Statement).

03. Books

(a) Authored

(b) Edited
1. Russell JA, Walley KR. Acute Respiratory Distress Syndrome: A comprehensive clinical approach. Cambridge University Press. 356 pages; 14 chapters; 22 authors. 1999

(c) Chapters
1. Russell JA. Should lactic acidosis be corrected? Update Intensive Care and Emergency Medicine. 14:105-112. 1991
2. Russell JA. Oxygen delivery and consumption in adult respiratory distress syndrome and sepsis. Update Intens Emerg Med. 14:175-181. 1991
3. Russell JA. Pathophysiology of acute respiratory failure. Chest Surgery Clinics of North America. 1(2):209-238. 1991
4. Herbertson MJ, Cunningham K, Russell JA. The adult respiratory distress syndrome. Current Opinions in Anesthesiology. 5(2):218-224. 1992
5. Montaner JSG, Phillips P, Russell JA. AIDS in the Intensive Care Unit. In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood Editors. McGraw-Hill Publishers. Chapter 100:1208-1231. 1992
6. Russell JA. Oxygen delivery/consumption relationships are not altered in the critically ill. Sem Resp Crit Care Med. 15(5):403-418. 1995
7. Baigorri F, Russell JA. Oxygen delivery in critical illness. Critical Care Clinics. 12(4); 971-994. 1996
8. Chittock DR, Russell JA. Oxygen delivery/consumption during sepsis. Clinics in Chest Medicine. 17(2):263-278. 1996
9. Russell JA. Fluid strategy in ARDS: The concept of maintaining peripheral perfusion. In: Current Topics in Intensive Care. W.B. Saunders Company Ltd., London, UK. Vol. 4:17-42. 1997
10. Russell JA. Serum Lactate: Marker of prognosis not inadequacy of oxygen delivery. 1st International Meeting of Applied Physiology of the Peripheral Circulation: Splanchic Circulation (in press) Springer Verlag Publishers.
11. Montaner JSG, Phillips P, Russell JA. AIDS in the Intensive Care Unit. Chapter 44, Pages 773-802 In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood, Editors. McGraw Hill Publishers. 2nd Edition. 1998
12. Forrest D, Russell JA. Metabolic acidosis: Pathophysiology and causes. Chapter 8.3.1. Pages 573-577 In: Oxford Textbook of Critical Care. Oxford University Press. 1999
13. Forrest D, Russell JA. Metabolic acidosis: Therapeutic Strategy. Chapters 8.3.2. Pages 577-581 In: Oxford Textbook of Critical Care. Oxford University Press. 1999
14. Chittock DR, Russell JA. Complications of fluid and hemodynamic management. Chapter 11, Pages 266-290. In: Complications in the Intensive Care Unit. Chapman and Hall, New York. 1997
15. Forrest D, Russell JA. Monitoring tissue oxygenation in the critically ill. Current Opinion in Critical Care. 3(1):7-15 Rapid Science Publishers 1997
16. Russell JA. Hypotension and Shock. In: Chapter 18, Pages 150-157. On Call. W.B. Saunders (2nd Edition). 1993
17. Russell JA. The effects of mechanical ventilation on oxygen delivery and consumption. Chapter 10, Pages 345-74: In: Mechanical Ventilation. Editors: Marini J, Slutsky A. Published as part of a series on Lung Biology in Health and Disease. 1997
18. Chittock DR, Ronco JJ, Russell JA. Oxygen transport and oxygen consumption. Chapter 20, Pages 317-344.In: Principles and Practice of Intensive Care Monitoring. McGraw Hill Publishers. 1998
19. Gregoire G, Russell JA. Triage and severity of illness. Chapter 7, Pages 57-70. In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood Editors. McGraw Hill Publishers, 2nd Edition. 1998
20. Forrest D, Russell JA. Effects of metabolic acidosis on organ function. Chapter 4, Section 5. Pages 313-326. In: Critical Care Nephrology. Kluwer Academic Publishers, The Netherlands. 1998
21. Uusaro A, Russell JA. Multiple organ failure. In: Pulmonary and peripheral gas exchange in health and disease. In series: Lung Biology in Health and Disease. J Roca, R Rodrigeuz-Roisin, P Wagner. Marcel Dekker Inc Publisher. 2000
22. Russell JA, Walley KR. Introduction – Pages 1-5. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press. Editors: Russell JA, Walley KR. 1999
23. Dhingra V, Russell JA, Walley KR. Overview clinical evaluation and chest radiology of acute respiratory distress syndrome. Chapter 1, Pages 6-27. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press Editors: Russell JA, Walley KR. 1999
24. Walley KR, Russell JA. Pulmonary pathophysiology in ARDS. Chapter 5, Pages 80-106. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press. Editors: Russell JA, Wally KR. 1999
25. Walley KR, Russell JA. Cardiovascular management of ARDS. Chapter 6, Pages 107-138. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press. Editors: Russell JA, Walley KR. 1999
26. Russell JA, Dhingra V, Walley KR. Clinical assessment and total patient care. Chapter 9, Pages 183-232. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press. Editors: Russell JA, Walley KR. 1999
27. Uusaro A, Russell JA, Walley KR. Multiple system organ failure. Chapter 13, Pages 304-333. In: Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach. Cambridge University Press. Editors: Russell JA, Walley KR. 1999
28. Forrest DM, Russell JA, Montaner JSG. AIDS in the Intensive Care Unit: Focus on Pneumocystis carinii Pneumonia. In: Current Opinion in Critical Care. Volume 5. Issue 5, 1999; 5(5):368-375.
29. Holmes C, Russell JA. Vasopressin in the ICU. In: Current Opinion in Critical Care, 2004; 10 (6): 442 – 448.
30. Holmes C, Russell JA. Vasopressin. In: Seminars in Respiratory and Critical Care Medicine, 2004; 25(6):705 – 711.
31. Holmes C, Gregoire G, Russell JA. Assessment of severity of illness. Chapter 7, In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood editors. McGraw Hill Publishers, 3rd Edition, 2005.
32. Phillips P, Montaner JSG, Russell JA. AIDS in the Intensive Care Unit. Chapter 44, In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood, Editors. McGraw Hill Publishers. 3rd Edition, 2005.
33. Manocha S, Russell JA, Walley KR. Genetics of acute lung injury. In: Current Opinion in Critical Care. 2004.
34. Russell JA. Physician staffing in the intensive care unit in 2015. In: Update in Emergency and Intensive Care Medicine (Springer Verlag) 45:279-290, 2006.
35. Russell JA. Shock syndromes related to sepsis. Chapter 109, pages 755 – 763. In: Cecil Medicine. Goldman L, Ausiello D, Editors. Saunders Elsevier Publisher. 23rd Edition, 2008.
36. Russell JA. Vasopressin in vasodilatory and septic shock. In: Current Opinion in Critical Care 13(4): 383 – 391, 2007.
37. Gordon AC, Russell JA. Vasopressin in septic shock. In: Evidence Based Practise of Critical Care (2010). Deutschman C, Editor. Saunders Elsevier Publisher.
38. Russell JA. Shock syndromes related to sepsis. Chapter 108, pages 658-666. In: Goldman’s Cecil Medicine. Goldman L, Ausiello D, Editors. Saunders Elsevier Publisher. 23rd Edition, 2014.
39. Russell JA. Assessment of severity of illness. Chapter, In: Principles of Critical Care. JB Hall, GA Schmidt editors. McGraw Hill Publishers, 4th Edition, 2014 (In press).
40. Hall M, Linder A, Montaner JSG, Russell JA. HIV and AIDS in the Intensive Care Unit. In: Principles of Critical Care. JB Hall, GA Schmidt, LDH Wood, Editors. McGraw Hill Publishers. 4th Edition, 2014 (In press).
41. Russell JA, Nakada T. Treatment of fever. In: Evidence Based Practise of Critical Care. Deutschman C, Editor. Saunders Elsevier Publisher, 2nd Edition, 2015, pp 212 – 217.
42. Russell JA, Linder A, Sweet D, Boyd J, Walley KR. Advances in Sepsis (Chapter 18). In Lalwani AK and Pfister MHF (eds). Recent Advances in Otolaryngology-Head and Neck Surgery, 4th Edition, Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India, 2015, pp. xxx-xxx.
43. Genga K, Russell JA. Coagulation abnormalities in sepsis. In: Critical Care Nephrology. Invited chapter – In press.
44. Russell JA. Shock syndromes related to sepsis. Chapter 100, pages XX – XX. In: Goldman’s Cecil Medicine, 2019. Goldman L, Ausiello D, Editors. Saunders Elsevier Publisher. 23rd Edition (In press).
45. Roveran Genga K, Trinder M, Russell JA. How have genomics informed our understanding of critical illness? Chapter 5, pages 23 – 35. In: Evidence Based Practise of Critical Care. Deutschman C, Editor. Saunders Elsevier Publisher, 3rd Edition, 2018 (In press).

04. Patents – 12 patents regarding genomic and pharmacogenomic biomarkers.

1. Protein C Polymorphisms, U.S. Patent No. 7,820,376. European Patent No. 1507872.
2. Plasminogen Activator Inhibitor-1 (PAI-1) Haplotypes Predict Outcome in Critically Ill Patients, US # 105/549,804
3. Endothelial Protein C Receptor Polymorphisms Predict Outcome in Patients with Systemic Inflammatory Response, US # 10/591,263
4. Thrombomodulin Polymorphisms Predict Outcome in Patients with Systemic Inflammatory Response Syndrome, US# 10/591,325
5. TLR2 Polymorphisms Predict Incidence and Type of Infection in Patients with Systemic Inflammatory Response Syndrome, US# 10/591,224
6. Coagulation Factor 3 (Tissue Factor) Polymorphisms Predict Outcome in Patients with Systemic Inflammatory Response Syndrome, US# 12/090,613
7. Interferon Gamma Polymorphism Predicts Outcome in Patients with Systemic Inflammatory Response Syndrome, US# 12/304,104
8. Vasopressin Pathway Gene Polymorphisms Predict Outcome in Critically Ill Patients, US#12/162,066
9. Improved Response Polymorphisms for XIGRISTM, US# 12/160,889
10. Serpine1 Polymorphisms are Predictive of Risk of Death and Response to Activated Protein C Administration, US# 12/295,232
11. MAP3K14 Polymorphisms as Indicators of Subject Outcome in Critically Ill Subjects
12. Methods and uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors, US# 61/648,319

People

Faculty

Dr. James A. Russell